Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Becker Muscular Dystrophy - A Natural History Study to Predict Efficacy of Exon Skipping

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by Cooperative International Neuromuscular Research Group
Sponsor:
Information provided by (Responsible Party):
Cooperative International Neuromuscular Research Group
ClinicalTrials.gov Identifier:
NCT01539772
First received: February 22, 2012
Last updated: October 10, 2014
Last verified: October 2014
  Purpose

This is a multi-center natural history study that will be conducted at participating centers in the Cooperative International Neuromuscular Research Group (CINRG). Following a baseline evaluation, participants will have three follow-up visits over a three-year period. The investigators will characterize the Becker muscular dystrophy phenotype, and correlate specific abnormal dystrophin proteins with the range of clinical outcomes.


Condition
Becker Muscular Dystrophy

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: PITT0112: Becker Muscular Dystrophy - A Natural History Study to Predict Efficacy of Exon Skipping

Resource links provided by NLM:


Further study details as provided by Cooperative International Neuromuscular Research Group:

Estimated Enrollment: 80
Study Start Date: April 2012
Estimated Study Completion Date: March 2017
Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)
Groups/Cohorts
Becker

BMD participants over 4 years of age with in-frame deletions in the dystrophin gene.

.


Detailed Description:

We will utilize the Cooperative International Neuromuscular Research group (CINRG) network to collect cohorts of Becker muscular dystrophy (BMD) patients with in-frame deletions in the dystrophin gene. We will collect clinical data across multiple body systems and correlate these findings to the high-resolution deletion break-point mapping performed from the tissue samples. We will investigate the observed variability to deepen our understanding of molecular mechanisms relevant to the optimization of exon skipping therapeutic approaches.

  Eligibility

Ages Eligible for Study:   4 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

BMD participants over 4 years of age with specific in-frame deletions that correspond to the mutations generated by exon skipping of exons 45, 51 or 53

Criteria

Inclusion Criteria:

  • Male
  • Age 4 or older
  • Diagnosis of BMD with an in-frame deletion in the dystrophin gene, where the boundaries of the mutations are confirmed.

Exclusion Criteria:

• Investigator assessment of inability to comply with protocol

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01539772

Contacts
Contact: Lauren P Hache, MS, CGC 412-224-2030 lhache@childrensnational.org
Contact: Andrea Smith, MS, CGC 412-383-7207 smithal7@upmc.edu

Locations
United States, California
University of California Davis Recruiting
Sacramento, California, United States
Contact: Candace Aguilar    916-734-8898    pmr.research@ucdmc.ucdavis.edu   
Principal Investigator: Craig McDonald, MD         
United States, District of Columbia
Children's National Health System Recruiting
Washington, District of Columbia, United States
Contact: Allyn Toles    202-476-4802    AToles2@childrensnational.org   
Principal Investigator: Mathula Thangarajh, MD         
United States, Illinois
Ann & Robert H. Lurie Children's Hospital of Chicago Recruiting
Chicago, Illinois, United States
Contact: Lauren Webb    312-227-4483    lwebb@luriechildrens.org   
Principal Investigator: Nancy Kuntz, MD         
United States, Minnesota
University of Minnesota Recruiting
Minneapolis, Minnesota, United States
Contact: Gina Chambers       gchamber@umn.edu   
Principal Investigator: Peter Karachunski, MD         
United States, Missouri
Washington University Recruiting
St. Louis, Missouri, United States
Contact: Traci Christenson    314-362-6991    christensont@neuro.wustl.edu   
Principal Investigator: Anne Connolly, MD         
United States, North Carolina
Carolinas Medical Center Recruiting
Charlotte, North Carolina, United States
Contact: Jackie Sykes    704-333-3967    Jacqueline.Sykes@carolinashealthcare.org   
Principal Investigator: Susan Sparks, MD, PhD         
Duke Children's Hospital and Health Center Recruiting
Durham, North Carolina, United States
Contact: Karen Cornett    919-684-1143    k.cornett@duke.edu   
Principal Investigator: Edward Smith, MD         
Principal Investigator: Priya Kishnani, MD         
United States, Pennsylvania
Penn State Hershey Medical Center Recruiting
Hershey, Pennsylvania, United States, 17033
Contact: Heidi Runk    717-531-0003    hrunk@hmc.psu.edu   
Principal Investigator: Matthew Wicklund, MD         
University of Pittsburgh Recruiting
Pittsburgh, Pennsylvania, United States
Contact: Andrea Smith, MS, CGC    412-383-7207    smithal7@upmc.edu   
Principal Investigator: Paula Clemens, MD         
Sub-Investigator: Hoda Abdel-Hamid, MD         
United States, Tennessee
University of Tennessee Recruiting
Memphis, Tennessee, United States
Contact: Meegan Barrett-Adair    901-725-8920    mbarret9@uthsc.edu   
Principal Investigator: Tulio Bertorini, MD         
United States, Texas
Texas Children's Hospital Recruiting
Houston, Texas, United States
Contact: Aryn Knight, MPH       axknight@texaschildrens.org   
Principal Investigator: Timothy Lotze, MD         
Argentina
Fundacion Favaloro Not yet recruiting
Buenos Aires, Argentina
Contact: Lorena Levy       lonale75@fibertel.com.ar   
Contact: Luz Andreone       luzandreone@hotmail.com   
Principal Investigator: Alberto Dubrovsky, MD         
Canada, Alberta
Alberta Children's Hospital Recruiting
Calgary, Alberta, Canada
Contact: Jean Mah, MD       jean.mah@albertahealthservices.ca   
Principal Investigator: Jean Mah, MD         
United Kingdom
Institute of Genetic Medicine - Newcastle University Not yet recruiting
Newcastle upon Tyne, United Kingdom
Contact: Becky Davis    01912418649    becky.davis@ncl.ak.uk   
Principal Investigator: Michela Guglieri, MD         
Sponsors and Collaborators
Cooperative International Neuromuscular Research Group
Investigators
Study Chair: Paula R Clemens, MD University of Pittsburgh
  More Information

No publications provided

Responsible Party: Cooperative International Neuromuscular Research Group
ClinicalTrials.gov Identifier: NCT01539772     History of Changes
Other Study ID Numbers: PITT0112
Study First Received: February 22, 2012
Last Updated: October 10, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Genetic Diseases, Inborn
Genetic Diseases, X-Linked
Muscular Diseases
Muscular Disorders, Atrophic
Musculoskeletal Diseases
Nervous System Diseases
Neuromuscular Diseases

ClinicalTrials.gov processed this record on November 20, 2014